Use of Statins and the Risk of Parkinson???s Disease
- 1 January 2008
- journal article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 31 (5), 399-407
- https://doi.org/10.2165/00002018-200831050-00004
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do notBrain Research, 2007
- Psychiatric Adverse Reactions with Statins, Fibrates and EzetimibeDrug Safety, 2007
- Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's diseaseMovement Disorders, 2006
- Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD ratsNeuroscience Letters, 2006
- Atorvastatin may cause nightmaresBMJ, 2006
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- The General Practice Research DatabaseDrug Safety, 2004
- Oxidative stress in Parkinson's diseaseAnnals of Neurology, 2003
- Increased Risk of Parkinson's Disease in Relatives of PatientsAnnals of Neurology, 1995
- Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled StudyThe Journal of Clinical Pharmacology, 1993